The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening

Abstract excerpt

<h4>Background: </h4> Adjuvant Temozolomide is considered the front-line Glioblastoma chemotherapeutic treatment; yet not all patients respond. Latest trends in clinical trials usually refer to Doxorubicin; yet it can lead to severe side-effects if administered in high doses. While Glioblastoma prognosis remains poor, little is known about the combination of the two chemotherapeutics. <h4>Methods: </h4>: Patient-...

Topics

Open a Topic to create a Post that cites this publication.

• Anilides
• Brain Metastases and Treatment
• Cancer Mechanisms and Therapy
• Coculture Techniques
• Glioma Diagnosis and Treatment
• Histone Deacetylase Inhibitors Research
• Protein Degradation and Inhibitors
• Ubiquitin and proteasome pathways

Identifiers and source

Literature Corpus work

4c9ee522-68ee-5aab-b27e-f50d66231e0d

DOI

10.21203/rs.3.rs-3203171/v1